Non-covalent inhibitors of thioredoxin glutathione reductase with schistosomicidal activity in vivo

Abstract Only praziquantel is available for treating schistosomiasis, a disease affecting more than 200 million people. Praziquantel-resistant worms have been selected for in the lab and low cure rates from mass drug administration programs suggest that resistance is evolving in the field. Thioredox...

Celý popis

Podrobná bibliografie
Hlavní autoři: Valentina Z. Petukhova, Sammy Y. Aboagye, Matteo Ardini, Rachel P. Lullo, Francesca Fata, Margaret E. Byrne, Federica Gabriele, Lucy M. Martin, Luke N. M. Harding, Vamshikrishna Gone, Bikash Dangi, Daniel D. Lantvit, Dejan Nikolic, Rodolfo Ippoliti, Grégory Effantin, Wai Li Ling, Jeremy J. Johnson, Gregory R. J. Thatcher, Francesco Angelucci, David L. Williams, Pavel A. Petukhov
Médium: Článek
Jazyk:English
Vydáno: Nature Portfolio 2023-06-01
Edice:Nature Communications
On-line přístup:https://doi.org/10.1038/s41467-023-39444-y